Palvella Wins FDA Priority Review for QTORIN After Positive Phase 3 Results

Palvella Therapeutics announced on October 28, 2026, that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for QTORIN™ 3.9% rapamycin anhydrous gel and granted Priority Review for the treatment of microcystic lymphatic malformations (LMs). The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027.

The latest decision follows a series of regulatory milestones. The FDA granted rolling review to QTORIN rapamycin on June 22, 2026, allowing the agency to begin evaluating completed sections of the NDA before the full application was submitted. Palvella submitted the first module on June 29 and completed the rolling NDA submission on August 31, 2026. The subsequent acceptance for filing and Priority Review mark the transition to formal review of the completed application.

If approved, QTORIN rapamycin could become the first FDA-approved treatment specifically for microcystic LMs, a rare, chronic condition affecting an estimated more than 30,000 diagnosed children and adults in the United States.

Phase 3 SELVA Results Support Regulatory Application

The NDA is supported by results from the Phase 3 SELVA study (NCT06239480), which met its primary endpoint, prespecified key secondary endpoint and four additional secondary efficacy endpoints. All six endpoints achieved statistical significance, with p-values below 0.001.

SELVA evaluated once-daily QTORIN rapamycin in a single-arm, baseline-controlled study. Among participants aged six years and older included in the primary efficacy analysis, the treatment produced a mean improvement of 2.13 points at Week 24 on the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA).

Among the 43 participants who completed the efficacy evaluation period, 41 (95%) demonstrated improvement of at least one point on the mLM-IGA. Additionally, 37 participants (86%) were rated as “Much Improved” or “Very Much Improved.”

The key secondary endpoint, assessed using a blinded photographic review of lesion severity, also improved significantly. The mean score on the microcystic LM Multi-Component Static Scale decreased by 3.36 points at Week 24, reflecting changes in lesion height, leaking or bleeding, and vesicle appearance.

Although these findings support further evaluation of QTORIN rapamycin, the single-arm design limits direct comparisons with existing treatments. The results therefore establish improvement relative to baseline rather than superiority over surgery, sclerotherapy, laser procedures or other therapies.

Safety Findings and Systemic Exposure

Palvella reported that QTORIN rapamycin was generally well tolerated in SELVA, with no drug-related serious adverse events. Systemic rapamycin concentrations remained below 2 ng/mL at all measured time points in all participants.

The broader safety findings provide additional context. Among the 50 participants who initiated treatment, 35 experienced treatment-emergent adverse events. Four participants experienced serious adverse events, all assessed by investigators as unrelated to the study drug. Seventeen participants experienced treatment-related adverse events, all rated mild or moderate. One participant discontinued treatment because of lymphorrhea, which investigators considered possibly related to the drug.

These results provide initial safety information for the topical formulation. However, the study findings do not establish long-term safety, and further follow-up will be important for a condition that may require prolonged treatment.

FDA Designations and Unmet Medical Need

QTORIN rapamycin has received FDA Breakthrough Therapy, Fast Track and Orphan Drug designations for microcystic LMs. The development programme has also received grant funding from the FDA Office of Orphan Products Development. The NDA includes Phase 2 clinical results, published literature and other evidence concerning off-label rapamycin use in microcystic LMs.

Microcystic LMs involve malformed lymphatic vessels that can protrude through the skin, leak lymphatic fluid, bleed and cause recurrent infections, including cellulitis that may require hospitalisation. The condition can persist and progress over time, leading to repeated interventions and substantial disease burden.

Current management options include surgery, sclerotherapy and laser procedures, but recurrence and the need for repeated treatment remain challenges. Systemic therapies targeting the PI3K/mTOR pathway may also raise concerns about long-term tolerability and systemic exposure.

There are currently no FDA-approved treatments specifically for microcystic LMs in the United States.

Potential U.S. Launch in First Half of 2027

Palvella is preparing for a potential standalone U.S. commercial launch in the first half of 2027, subject to FDA approval. Its preparations include engagement with treating specialists, disease education, patient identification, market access planning and patient support services.

The company is also developing QTORIN rapamycin for cutaneous venous malformations and clinically significant angiokeratomas, alongside QTORIN pitavastatin for disseminated superficial actinic porokeratosis.

Clinical Significance

FDA acceptance and Priority Review move QTORIN rapamycin closer to a potential first approved treatment for microcystic LMs. The SELVA results show statistically significant improvements across prespecified efficacy measures, alongside low measured systemic exposure and no drug-related serious adverse events.

The next key milestone is the FDA’s regulatory decision. Until approval, QTORIN rapamycin remains investigational. Its eventual clinical role will depend on the agency’s assessment of the full evidence package, including the efficacy findings, safety profile and limitations of the available clinical data.

Reference

Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set, Palvella Therapeutics, 28 October 2026

Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations, Palvella Therapeutics, 24 February 2026

SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations (SELVA), ClinicalTrials.gov ID NCT06239480